US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco S&P SmallCap Health Care ETF

52.95

-0.1582-0.30%

Post-market: 52.92-0.0316-0.06%19:30 EDT

Volume:6K

Turnover:303.64K

Market Cap:178.45M

PE:- -

High:53.80

Open:53.80

Low:52.92

Close:53.11

52wk High:56.45

52wk Low:39.08

Shares:3.37M

Float Shares:3.37M

Volume Ratio:0.52

T/O Rate:0.17%

Dividend:0.00

Dividend Rate:0.01%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says

MT Newswires Live

Krystal Biotech, Inc. : RBC Initiates Coverage with Outperform Rating; Target Price $400

THOMSON REUTERS

BrightSpring Health Svcs Price Target Maintained with a $90.00/Share by BTIG

BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D

Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding

Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks

Corcept Chief Development Officer William Guyer Disposes of Common Shares Worth $1.85 Million

Alkermes Cuts Interest Spreads on $1.52 Billion Term Loan Facilities Via Credit Agreement Amendment

Alkermes - Enters Amendment No. 1 to Credit Agreement on August 12, 2026 - SEC Filing

THOMSON REUTERS

Alkermes - Amendment Reduces Interest Rate Spread Under Tla by 0.75% and Tlb by 0.50% - SEC Filing

THOMSON REUTERS

Health Insurers are Dumping Medicare Advantage Plans. Here's How Many Seniors Could be Affected.

8 ‘trendsetter’ stocks for world’s top mega-trends: Jon Erlichman

The Race to Come up with the Next Big Sleep Drug

Corcept Therapeutics (CORT) Stock Could Be Undervalued Despite Mixed Broader Checks

Simply Wall St.

Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1

Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon Disposes of 1,540 Common Shares Worth $175,806.40

Arcutis Q2 Revenue Rises on Demand for Zoryve, Lifts 2026 Sales Outlook

United Therapeutics Q2 Revenue Misses Estimates on Ebulized Tyvaso Weakness

Ultragenyx Q2 Revenue Rises 28% to Record High, Net Loss Narrows

Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $98,821.72

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/PSCH/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PSCH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSCH\",,,,,undefined,":{"symbol":"PSCH","market":"US","secType":"STK","nameCN":"Invesco S&P SmallCap Health Care ETF","latestPrice":52.9516,"timestamp":1789156800000,"preClose":53.1098,"halted":0,"volume":5705,"hourTrading":{"tag":"盘后","latestPrice":52.92,"preClose":52.9516,"latestTime":"19:30 EDT","volume":9,"amount":476.6064,"timestamp":1789169406564,"change":-0.0316,"changeRate":-0.000597,"amplitude":0},"delay":0,"changeRate":-0.0029787346214823025,"floatShares":3370000,"shares":3370000,"eps":0,"marketStatus":"Market Closed","change":-0.1582,"latestTime":"09-11 16:00:00 EDT","open":53.8,"high":53.8,"low":52.92,"amount":303636.23374,"amplitude":0.016569,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":53.1098,"sharesOutstanding":3220000,"nav":53.15922,"aum":179678163.6,"dividendRate":0.000057,"bidAskSpread":0.001721,"postHourTrading":{"tag":"盘后","latestPrice":52.92,"preClose":52.9516,"latestTime":"19:30 EDT","volume":9,"amount":476.6064,"timestamp":1789169406564,"change":-0.0316,"changeRate":-0.000597,"amplitude":0},"volumeRatio":0.5187589709043396,"impliedVol":0.1092,"impliedVolPercentile":0.7052},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSCH\",,,,,undefined,":{"symbol":"PSCH","floatShares":3370000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.5187589709043396,"shares":3370000,"dividePrice":0.003,"high":53.8,"amplitude":0.016569,"preClose":53.1098,"low":52.92,"week52Low":39.08,"pbRate":"--","week52High":56.454,"institutionHeld":0,"latestPrice":52.9516,"eps":0,"divideRate":0.000057,"volume":5705,"delay":0,"ttmEps":0,"open":53.8,"prevYearClose":44.0553,"prevWeekClose":54.3614,"prevMonthClose":54.61,"prevQuarterClose":52.3666,"fiveDayClose":54.7539,"twentyDayClose":54.9289,"sixtyDayClose":48.0495},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSCH\",params:#limit:5,,,undefined,":[{"date":"2026-03-23","symbol":"PSCH","amount":0.00033,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-09-22","symbol":"PSCH","amount":0.00259,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"PSCH","amount":0.00199,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-24","symbol":"PSCH","amount":0.01419,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-24","defaultRemindTime":1742823000000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-24","currency":"USD","dateTimestamp":1742788800000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSCH","amount":0.01801,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSCH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-30","value":0.01949,"currency":"USD"},{"executeDate":"2018-09-24","recordDate":"2018-09-25","paymentDate":"2018-09-28","value":0.00522,"currency":"USD"},{"executeDate":"2022-03-31","recordDate":null,"paymentDate":"2022-03-31","value":3,"currency":"USD"},{"executeDate":"2023-12-18","recordDate":"2023-12-19","paymentDate":"2023-12-22","value":0.00448,"currency":"USD"},{"executeDate":"2024-03-18","recordDate":"2024-03-19","paymentDate":"2024-03-22","value":0.03613,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSCH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSCH\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659140246","title":"Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2659140246","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659140246?lang=en_us&edition=fundamental","pubTime":"2026-08-14 23:11","pubTimestamp":1786720282,"startTime":"0","endTime":"0","summary":"Krystal Biotech  has further room for gains driven by Vyjuvek, its treatment for the rare blistering condition dystrophic epidermolysis bullosa, alongside international launches and growth across its gene therapy pipeline, RBC Capital said Friday in a report.Krystal's neurotrophic keratitis program could be its next major catalyst, with pivotal data expected in early 2027, RBC said. Shares may rise 30% if results match the current standard of care, while a weak outcome might prompt a 15% decline, the report said.RBC forecasts peak NK sales of $2.1 billion in 2030, citing the established market and potential for the therapy to become a best-in-class treatment, though the outlook remains \"cautiously optimistic\" given limited clinical data.Vyjuvek holds more than 60% of the US market, while international launches are expected to drive the next phase of growth, the report said. RBC projects Vyjuvek peak sales of $1 billion by 2033 and pointed to H2 readouts in ocular DEB, cystic fibrosis a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","PSCH","HELX","BK4588","KRYS","BK4581","BK4139","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659428117","title":"Krystal Biotech, Inc. : RBC Initiates Coverage with Outperform Rating; Target Price $400","url":"https://stock-news.laohu8.com/highlight/detail?id=2659428117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659428117?lang=en_us&edition=fundamental","pubTime":"2026-08-14 17:39","pubTimestamp":1786700394,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nFWN44B0NL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KRYS","PSCH","HELX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659156635","title":"BrightSpring Health Svcs Price Target Maintained with a $90.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2659156635","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659156635?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:03","pubTimestamp":1786618980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BTSG/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BTSG","PSCH","LU2324357040.USD","PTH","LU2089984988.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155684243","title":"BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=1155684243","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155684243?lang=en_us&edition=fundamental","pubTime":"2026-08-13 12:50","pubTimestamp":1786596641,"startTime":"0","endTime":"0","summary":"BofA Securities has released a report indicating that the Chinese CXO sector is poised to benefit from robust biotech venture capital funding. The bank notes that strong financing in the first half...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2045819591.USD","LU0456842615.SGD","SURI","BK0216","BBC","LU1770034418.SGD","LU1251922891.USD","LU0052750758.USD","LU1997245177.USD","LU1969619763.USD","BMED","SMCO","LU2488822045.USD","IDNA","FHLC","LU1934453819.USD","LU1719994722.HKD","LU1979443071.USD","LU0320764599.SGD","LU1046422090.SGD","MEDI","IBRN","LU1997244956.HKD","LU1997245094.SGD","WX","LU2328871848.SGD","LU2125910500.SGD","LU0611395673.USD","LU0348766576.USD","LU0700851271.USD","LU2242644610.SGD","LU2495084118.USD","161027","BK1576","IE00BPRC5H50.USD","PSIL","IE00B543WZ88.USD","603259","LFSC","LU0348767384.USD","LU0708995583.HKD","02359","BK1583","IE00B5MMRT66.SGD","LU1808992512.USD","PSCH","LU1303224171.USD","CXO","APXH","XBIX","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111112440","title":"Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=1111112440","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111112440?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:35","pubTimestamp":1786588544,"startTime":"0","endTime":"0","summary":"A report from Bank of America Securities indicates that Chinese CRO/CDMO companies are poised to benefit from robust first-half funding in the global and Chinese biotech sectors, along with active...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002463.SGD","LU2328871848.SGD","03759","LU0700851271.USD","LU0348735423.USD","LU0516422952.EUR","LU1794554557.SGD","LU2488822045.USD","LU0359201612.USD","LU1997245177.USD","02269","LU0327786744.USD","LU0588546209.SGD","LU0456842615.SGD","LU1997244956.HKD","LU0417516902.SGD","PSIL","FHLC","LU0029874061.USD","LU0823426480.USD","LU1688375341.USD","LU1934453819.USD","LU0708995583.HKD","LU0348767384.USD","LU1979443071.USD","MEDI","BK1610","SMCO","LU1242518931.SGD","LU1251922891.USD","LU0348766576.USD","LU2495084118.USD","LU0456827905.SGD","LU0823426308.USD","BK0216","BK1521","LU1719994722.HKD","IDNA","LU0051755006.USD","LU0417516738.SGD","LU0856984785.SGD","IE00B543WZ88.USD","CXO","XBIX","LU3063872942.SGD","LU0572944931.SGD","603259","BMED","LU0456846285.SGD","LU0516423174.USD","161027","PSCH","02359","WX","LU0516422440.USD","LU0611395673.USD","LU1880383366.USD","LU0039217434.USD","IE00B5MMRT66.SGD","LU1242518857.USD","LU0307460666.USD","LU0516423091.SGD","BK1141","LU2242644610.SGD","KURE","BK1583","LU1303224171.USD","IBRN","LU0181495838.USD","LU0326950275.SGD","LFSC","BK1589","BK1576","IE00BPRC5H50.USD","LU0043850808.USD","LU2045819591.USD","LU1969619763.USD","LU1997245094.SGD","LU2039709279.SGD","LU0819121731.USD","LU0979878070.USD","LU1808992512.USD","LU1046422090.SGD","LU1770034418.SGD","LU0052750758.USD","LU0359202008.SGD","LU0320764599.SGD","LU0348825331.USD","IE00B0JY6N72.USD","LU1720050803.USD","APXH","BBC","LU0516422366.SGD","LU2125910500.SGD","SURI","LU0128526141.USD","LU0140636845.USD","SG9999002562.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659926188","title":"Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2659926188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659926188?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:37","pubTimestamp":1786567029,"startTime":"0","endTime":"0","summary":"The latest update is out from Outlook Therapeutics ( ($OTLK) ). On July 24, 2026, Outlook Therapeutics announced U.S. FDA approval of LYTENAVA (bev...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","XLVX","MRNY","PSCH","IYH","BMED","FRTY","BK4588","IDNA","BK4539","IEIH","SYNB","LENZ","GDOC","RSPH","TECB","LFSC","GNMX","BK4585","BK4139","NVIB","BK4007","LABU","PINK","MEDI","TBXU","BBP","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659900794","title":"Corcept Chief Development Officer William Guyer Disposes of Common Shares Worth $1.85 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659900794","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659900794?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:27","pubTimestamp":1786566428,"startTime":"0","endTime":"0","summary":"Corcept Chief Development Officer William Guyer disposes of common shares worth $1.85 millionCorcept disclosed Chief Development Officer William Guyer exercised options for 16,300 shares at $ 21.65 on","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL2qSVvx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Chief Development Officer William Guyer Disposes of Common Shares Worth $1.85 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","CORT","LU0566484027.USD","BK4007","LU1559883803.SGD","PSCH","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658906555","title":"Alkermes Cuts Interest Spreads on $1.52 Billion Term Loan Facilities Via Credit Agreement Amendment","url":"https://stock-news.laohu8.com/highlight/detail?id=2658906555","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658906555?lang=en_us&edition=fundamental","pubTime":"2026-08-12 23:19","pubTimestamp":1786547988,"startTime":"0","endTime":"0","summary":"Alkermes cuts interest spreads on $1.52 billion term loan facilities via credit agreement amendmentAlkermes entered an amendment on Aug. 12, 2026 to its Feb. 12, 2026 credit agreement with JPMorgan Chase Bank.The deal covers senior secured term loan A of USD 745.31 million, due Feb. 12, 2031, and term loan B of USD 773.06 million, due Aug. 12, 2031.The amendment cuts the interest spread by 0.75% on the term loan A facility, 0.5% on the term loan B facility.Term loan A now prices at Term SOFR plus 1.75%-2.25%, or base rate plus 0.75%-1.25%, based on secured net leverage.Term loan B now prices at Term SOFR plus 2.25%, or base rate plus 1.25%.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL3L5Jbs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IXG","LU1162221912.USD","JPX","LU2237443622.USD","PSIL","UYG","LU1363072403.SGD","TFNS","FTXO","LU2505996681.GBP","LU2023250843.SGD","LU0265550946.USD","IBRN","PSCH","LU2552382132.HKD","VFH","LU2357305700.SGD","LU0345770993.USD","LU0106261372.USD","IE00BYXW3230.USD","LU0208291251.USD","FNCL","XLF","LU0320765489.SGD","LU0320765646.SGD","LU2552382215.SGD","FBT","IE00BZ1G4Q59.USD","LU0234572021.USD","LU2054465674.USD","KBWB","LU0211326755.USD","LU1551013425.SGD","ALKS","IYF","LU1496350502.SGD","JPO","LU1116320901.HKD","LU1974910355.USD","LU2106854487.HKD","LU1629891620.HKD","LU2462157665.USD","LU2456880835.USD","LU1720051017.SGD","LU0496365809.HKD","JPMO","MEDX","IYG","TRUF","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908840","title":"Alkermes - Enters Amendment No. 1 to Credit Agreement on August 12, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908840","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908840?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541257,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491BU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","ALKS","PSIL","PSCH","BK4139","MEDX","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908808","title":"Alkermes - Amendment Reduces Interest Rate Spread Under Tla by 0.75% and Tlb by 0.50% - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908808","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908808?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541257,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491BU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","FBT","ALKS","BK4139","IBRN","MEDX","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658391758","title":"Health Insurers are Dumping Medicare Advantage Plans. Here's How Many Seniors Could be Affected.","url":"https://stock-news.laohu8.com/highlight/detail?id=2658391758","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658391758?lang=en_us&edition=fundamental","pubTime":"2026-08-12 02:02","pubTimestamp":1786471320,"startTime":"0","endTime":"0","summary":"Coverage changes could leave rural markets with fewer choicesAbout 10% of the Medicare Advantage market was forced to find new plans in 2026. Coverage plans for 2027 will be finalized by Oct. 1.Older ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983260115.SGD","BK4588","MOH","BK4154","XLVX","LU0238689110.USD","LU1093756325.SGD","LU1093756168.USD","PSCH","BK4585","SG9999014013.SGD","BK4533","LU0390134368.USD","LU0211331839.USD","LU0320765489.SGD","LU0070302665.USD","LNGR","SG9999014021.USD","LU0256863811.USD","LU0266013472.USD","FXH","SG9999014005.SGD","BK4532","IEHS","BK4566","LU0348723411.USD","LU0417517546.SGD","LU0208291251.USD","XHS","LU0170899867.USD","IYH","SG9999014039.USD","UNHU","HUM","IHF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657646644","title":"8 ‘trendsetter’ stocks for world’s top mega-trends: Jon Erlichman","url":"https://stock-news.laohu8.com/highlight/detail?id=2657646644","media":"Bloomberg","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657646644?lang=en_us&edition=fundamental","pubTime":"2026-08-07 17:00","pubTimestamp":1786093200,"startTime":"0","endTime":"0","summary":"In the latest episode of Ticker Take, I spoke with Matt Orton of Raymond James Investment Management about that top-down approach, and the stocks he thinks fit it best.","market":"sg","thumbnail":"https://www.bnnbloomberg.ca/resizer/v2/ALRJGLKISQ5YQHT52J5GP2R3AQ.jpg?smart=true&auth=3cd1da2341d3279ac2053fa569f000b8d932710ca1ee4a201f166838db8d2c6d&width=500&height=333","type":0,"news_type":0,"thumbnails":["https://www.bnnbloomberg.ca/resizer/v2/ALRJGLKISQ5YQHT52J5GP2R3AQ.jpg?smart=true&auth=3cd1da2341d3279ac2053fa569f000b8d932710ca1ee4a201f166838db8d2c6d&width=500&height=333"],"rights":{"source":"bnn_bloomberg_highlight","url":"https://www.bnnbloomberg.ca/ticker-take/2026/08/07/8-trendsetter-stocks-for-worlds-top-mega-trends-jon-erlichman/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bnnbloomberg.ca/ticker-take/2026/08/07/8-trendsetter-stocks-for-worlds-top-mega-trends-jon-erlichman/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bnn_bloomberg_highlight","symbols":["XLK","LU2491050071.SGD","GB00BDT5M118.USD","BK4554","LU1506573853.SGD","LU2357125470.USD","MHIP","LU0882574055.USD","MULL","LU1988902786.USD","USXF","SGXZ99366536.SGD","MEDX","SG9999015952.SGD","IE0004445015.USD","LU0541501648.USD","LU2211815571.USD","LU0823434740.USD","BK4581","CRDU","MEMX","SG9999015978.USD","LU0124676726.USD","LU0384037296.USD","LU2211814178.USD","LU2023250330.USD","CGIC","LU1629891620.HKD","IE00BBT3K403.USD","LU2237438978.USD","FAI","SPWO","LU1974910355.USD","IXN","LU0980610538.SGD","LU1069344957.HKD","LU0823414478.USD","LU0488056044.USD","LU2491050154.USD","HBMX","LU0359202008.SGD","LU2089284900.SGD","BK4007","LU2931357623.SGD","IE00BJJMRY28.SGD","LU2168564222.USD","IE00BK4W5L77.USD","LU0965509283.SGD","LU1868836591.USD","LU1917777945.USD","PSCH","LU2357627491.SGD","LU2552382058.USD","LU1699723380.USD","LU1852331112.SGD","LU0289960550.SGD","LU2458330243.SGD","LU0820561909.HKD","LU2063271972.USD","LU2750360997.AUD","LU1064131342.USD","LU2491049909.HKD","IE0004086264.USD","LU1712237335.SGD","LU0256863902.USD","LU2360106947.USD","LU0081259029.USD","LU0079474960.USD","LU0238689110.USD","HVAC","LU2111349929.HKD","LU1868837565.USD","LU0203345920.USD","LU0006306889.USD","SG9999000418.SGD","LU0158827781.USD","BK4559","SG9999013999.USD","LU2249611893.SGD","LLYZ","IE00B775H168.HKD","LU0432979614.USD","LU0477156953.USD","LU2456880835.USD","SG9999001176.USD","FTEC","FHLC","SMH","IE00B19Z3581.USD","LU1989764748.USD","LU1267930730.SGD","BK4575","FSPC","LU2112291526.USD","CGDG","LU0320765059.SGD","LU0786609619.USD","BK4532","LU1035775433.USD","TTXU","LU1979441026.SGD","IE00BKDWB100.SGD","LU0122379950.USD","IE00BQXX3D17.EUR","LU1778281490.HKD","SG9999001424.SGD","LU1366192091.USD","IE00BFXG1179.USD","LU2756315318.SGD","LU1720051108.HKD","LU1551013425.SGD","LU0143863198.USD","IE00B5949003.HKD","LU1989764664.SGD","LU2092937221.SGD","IE00BJT1NW94.SGD","LU0757428866.USD","IE00BQXX3F31.USD","LU0672654240.SGD","LU1023059063.AUD","LU1983299246.USD","LU0823421333.USD","LU2264538146.SGD","LU1323610961.USD","LU0114720955.EUR","LU0456855351.SGD","LU0965509010.AUD","BLOX","LU0719512351.SGD","WDGF","LU0211327993.USD","LU2461242641.AUD","SPTE","LU0348723411.USD","LU1861220033.SGD","IE00BFXG0V08.USD","BK4533","EFIV","LU0964807845.USD","DISK","LU2360108059.USD","IE0002141913.USD","LU2237443622.USD","LU1815336091.USD","LU2265009873.SGD","CRDO","BK4187","IE0009356076.USD","LU0264606111.USD","LU0572940350.SGD","FDTX","MEDI","LU0133085943.USD","BK4548","LU0466842654.USD","SHOC","XLV","LU1934455194.USD","LU0211328371.USD","IE0002270589.USD","LU0106261372.USD","LU2756315664.SGD","LU2087625088.SGD","MUD","LU2125154935.USD","CHPX","IE00BD6J9T35.USD","LU0648001328.SGD","SOXX","TSMU","IE00BLSP4452.SGD","LU0689626769.HKD","LU0203202063.USD","SG9999001176.SGD","IE00B4R5TH58.HKD","LU0056508442.USD","BOBP","HRTS","LEGR","LU2552382215.SGD","LU0310799852.SGD","SOXQ","BK4141","KNOW","IE00BN8TJ469.HKD","BAI","TSMX","IE0001KFT4U8.USD","CURE","LU0572939691.SGD","LU2357305700.SGD","LU0162691827.USD","LU0878004406.USD","BK4602","EMSF","IE0005OL40V9.USD","LU0823421416.USD","LU2298321311.HKD","AVEM","SG9999015945.SGD","STSM","CHAT","LU2250418816.HKD","BK4526","IE00BLSP4239.USD","LU1674673691.USD","LU0154236417.USD","AVXC","BK4553","ADVE","LU2023250504.SGD","TRUH","LU2468319806.SGD","TSM","UMMA","BK4505","LU1868837722.USD","CORO","LU2065731478.USD","BK4579","LU1623119135.USD","SGXZ51526630.SGD","LU1093756325.SGD","LU1232071149.USD","LU2860962120.EUR","LU0823414551.USD","LU0225283273.USD","LU1366333091.USD","LU2746668461.USD","JDOC","LU0072461881.USD","LU2417539215.USD","LU2168563687.JPY","EMM","BK4534","IE00B1XK9C88.USD","LU0820562030.AUD","LU1868836914.USD","SG9999015986.USD","LU1934455863.HKD","LU0882574139.USD","LU2602419157.SGD","TSMG","LU1127390331.HKD","SGXZ31699556.SGD","XNTK","IE00BJJMRZ35.SGD","LU0289739699.SGD","LU1061106388.HKD","VHT","LU1291159041.SGD","BK4566","LU2290526834.HKD","WUGI","LU1868836757.USD","LU0859254822.USD","LU0642271901.SGD","BK4599","LU0471298694.HKD","LU2102340556.USD","GDOC","LU0708995401.HKD","TMED","LU2360032135.SGD","LU0385154629.USD","IE0034235303.USD","LU2471134523.USD","LU0097036916.USD","TSMY","IE000M9KFDE8.USD","WDNA","BK4196","LU2168564065.EUR","MIC","BK4605","BK4591","LU0058720904.USD","LU1804176565.USD","STRL","LLY","LU0889565833.HKD","LU2237443978.SGD","IE00BN29S564.USD","LU1280957306.USD","SGXZ81514606.USD","IE00BFSS8Q28.SGD","LU1720051017.SGD","LU2168564495.EUR","FTXH","LU2213496289.HKD","ASIA","LU0417517546.SGD","LU0234572021.USD","LU0878005551.USD","PJP","LU0174119429.USD","LU2247934214.USD","LU2054465674.USD","IE00BJLML261.HKD","LU0354030511.USD","LU2237443465.HKD","LU1548497426.USD","LU1868837136.USD","IE00B19Z3B42.SGD","IE0004091025.USD","LU0965509101.SGD","ELIS","LU0274383776.USD","LU2506951792.HKD","BK4612","LU2324357040.USD","LU2041044095.USD","TSMZ","IE00B2B36J28.USD","TTEQ","IE00B7KXQ091.USD","BK4503","LU2361044949.HKD","CGGO","RXL","CANC","IE00BFSS7M15.SGD","CNEQ","IETC","LU0861579265.USD","LU2237443549.SGD","LU0053671581.USD","LU0943347566.SGD","LU1057294990.SGD","LU0640476718.USD","IHE","IE00BYQQ9H92.USD","LU2286300806.USD","LU2360107168.USD","LU2361045086.USD","PTH","LU1145028129.USD","FXL","LLII","LU0792757196.USD","LU1674673428.USD","LU0157215616.USD","BK4512","BK4588","BK4527","IE00B5TLWC47.USD","LU0345770993.USD","LU0109392836.USD","LU0359201612.USD","LU0787776722.HKD","LU2458330169.SGD","LU1803068979.SGD","MUZ","LU0683600562.USD","LU0198837287.USD","LU0965508806.USD","LU2108987350.USD","LU0109391861.USD","LU0471298777.SGD","LU2237443382.USD","BK4550","LU0889566641.SGD","JGRO","IE00BQXX3C00.GBP","LU0345770308.USD","PSI","LU0359201885.HKD","PTF","ELIL","LU1914381329.SGD","LU1508157978.USD","LU2089984988.USD","LU0006061336.USD","LU2543165471.USD","PPH","CHPS","IE00BFTCPJ56.SGD","LU0061475181.USD","LU0130517989.USD","LU0175139822.USD","IYH","IE00BWXC8680.SGD","IE00BHPRN162.USD","LLYX","LU2896262040.SGD","SG9999014898.SGD","AIFD","IE00BK4W5M84.HKD","LU2237443895.HKD","CWI","LU2462157665.USD","BTSG","DRMY","LU0203201768.USD","LU1989771016.USD","EGGY","IE00B3M56506.USD","LU0823434583.USD","LU1282649067.USD","LU0096364046.USD","LU1571399168.USD","LU2048586759.USD","LU2403377893.USD","LU0210536198.USD","LU1201861249.SGD","LU0316494557.USD","SG9999017495.SGD","LU0266013472.USD","LU0256863811.USD","LU2089283258.USD","BK4516","EMC","IE0004445239.USD","LU2028103732.USD","WLDR","AVSE","MU","LU2663582299.SGD","LU0541502299.USD","LU0689472784.USD","LU1267930813.SGD","TRFK","RULE","LU2746668974.SGD","MUYY","ARTY","VGT","LU0354030438.USD","ESIM","AIS","LU2106854487.HKD","TEK","AIQ","OZEM","LU1023057109.AUD","LU1868837300.USD","LU0353189763.USD","LU1211504680.USD","LU0143863784.USD","SG9999014880.SGD","IXJ","LU0889565916.HKD","LU2750360641.GBP","LU2361044865.SGD","LU1093756168.USD","BK4129","LU0353189680.USD","MUU","THNR","AGNG","IE00BSNM7G36.USD","IE00BZ199S13.USD","LU0820561818.USD","LU2125154778.USD","LU0158827948.USD","IE00BKPKM429.USD","LU0082616367.USD","LU0823416689.USD","SG9999014906.USD","FTXL","IE0009355771.USD","LU2471134952.CNY","TINS","BK4585","LU1934455277.USD","LU1316542783.SGD","LU1282649810.SGD","LU2360106780.USD","LU2471134796.USD","LU0323591593.USD","LHX","LU2023251221.USD","LU0109394709.USD","SG9999018857.SGD","LU2552382132.HKD","AIRR","LU0314106906.USD","LU2168564149.EUR","BK4543","LU2294711713.HKD","LU2236285917.USD","LU2133065610.SGD","LU1989772923.USD","IE0009354923.USD","SG9999018865.SGD","LU2471134879.HKD","03145","LU1989772840.SGD","IE00B7SZLL34.SGD","LU0130102774.USD","LU0882747503.HKD","BK","CGNG","LU1551013342.USD","SG9999004220.SGD","LU0127658192.USD","IE00BJJMRX11.SGD","LU1861215975.USD","IE00B1BXHZ80.USD","LU1037948541.HKD","IE00B4JS1V06.HKD","LU2462591350.SGD","LU0320765992.SGD","LU1267930490.SGD","ILDR","LU0094547139.USD","SG9999014914.USD","LU1814569148.SGD","LU1868838027.USD","LU2089985449.USD","LU1037948897.HKD","LU2271345857.HKD","SGXZ57979304.SGD","BK4135","LU0203347892.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651052","title":"The Race to Come up with the Next Big Sleep Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651052","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651052?lang=en_us&edition=fundamental","pubTime":"2026-08-07 02:30","pubTimestamp":1786041000,"startTime":"0","endTime":"0","summary":"Narcolepsy isn't easy to treat. Existing drugs manage patients' symptoms -- notably excessive daytime sleepiness and difficulty sleeping at night -- rather than the cause. Yet a new type of drug is em","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ81514606.USD","IE00BN29S564.USD","LU0238689110.USD","LU0323591593.USD","IE00BKPKM429.USD","LU0097036916.USD","LU2023250330.USD","SG9999014914.USD","IE00BJJMRX11.SGD","LU0882574139.USD","LU0096364046.USD","LU1868837136.USD","LU2168564065.EUR","LU2023251221.USD","IE00BWXC8680.SGD","LU2746668974.SGD","TRUH","LU0256863902.USD","XLV","SG9999018865.SGD","SG9999018857.SGD","LU2471134952.CNY","LU0943347566.SGD","LU1323610961.USD","LU0109394709.USD","LU0672654240.SGD","SG9999014880.SGD","BK4007","LU0133085943.USD","IE0004445239.USD","LU0289739699.SGD","IE00B4R5TH58.HKD","LU0823434583.USD","LU2063271972.USD","SG9999015986.USD","LU2357305700.SGD","WDNA","LU2491049909.HKD","LU0109391861.USD","LU0787776722.HKD","LU1145028129.USD","BK4588","LU1988902786.USD","LU2236285917.USD","ILDR","LU0122379950.USD","LU2602419157.SGD","HRTS","LU2237438978.USD","LU2361044865.SGD","LU1712237335.SGD","LU0354030438.USD","ELIS","LU2462591350.SGD","LU0114720955.EUR","FTXH","CANC","IE00BJLML261.HKD","LU1868836757.USD","TAK","LU0820562030.AUD","IE00B1XK9C88.USD","LU0174119429.USD","LU0708995401.HKD","LU2237443895.HKD","LU2168564495.EUR","BK4516","LU1280957306.USD","BK4581","LU2491050071.SGD","AGNG","IE00BJJMRY28.SGD","IYH","LU1629891620.HKD","LU2746668461.USD","LU0471298777.SGD","LU0882574055.USD","BK4533","IE0002141913.USD","IE00BFTCPJ56.SGD","LU1069344957.HKD","LU2089984988.USD","IE00B1BXHZ80.USD","LLII","LU1720051108.HKD","SG9999001176.SGD","CURE","LU0203202063.USD","LU0466842654.USD","LU0820561909.HKD","LU0158827781.USD","LLY","LU2361045086.USD","LU0964807845.USD","BK4534","LLYZ","LU1720051017.SGD","LU0345770993.USD","LU0225283273.USD","MHIP","THNR","FBT","LU2106854487.HKD","LU0353189680.USD","LU1035775433.USD","LU1093756325.SGD","LU2417539215.USD","LU2756315318.SGD","LU2471134879.HKD","SG9999014898.SGD","LU0432979614.USD","LU2471134523.USD","LU2237443549.SGD","LU0345770308.USD","LU2168564222.USD","PSIL","BK4599","LU2324357040.USD","LU2361044949.HKD","LU2213496289.HKD","OZEM","LU0266013472.USD","LU2111349929.HKD","LU0456855351.SGD","LU2264538146.SGD","BK4585","IXJ","LU2089283258.USD","LU2552382215.SGD","RXL","IHE","LU2237443465.HKD","LU0210536198.USD","LU0320765059.SGD","LU0385154629.USD","IE0005OL40V9.USD","LU0106261372.USD","LU2896262040.SGD","SG9999015945.SGD","LU0158827948.USD","IBRN","ELIL","LU2462157665.USD","PPH","LU2552382132.HKD","LU2552382058.USD","SGXZ51526630.SGD","SGXZ99366536.SGD","LU2112291526.USD","LU0417517546.SGD","IE0004445015.USD","LU0058720904.USD","LU1232071149.USD","LU0203201768.USD","LU0320765992.SGD","LU1023059063.AUD","IE00B775H168.HKD","LU2456880835.USD","LU2750360641.GBP","LU2265009873.SGD","SG9999014906.USD","LU1064131342.USD","LU1291159041.SGD","LU0061475181.USD","IE00BJJMRZ35.SGD","PJP","LU1868837300.USD","LU1061106388.HKD","GDOC","LU0006306889.USD","LU0316494557.USD","LU0823416689.USD","LU1623119135.USD","LU1804176565.USD","LU2087625088.SGD","BK4139","SG9999017495.SGD","LU1868836914.USD","LU1366192091.USD","LU1551013425.SGD","LU2168563687.JPY","IE00B4JS1V06.HKD","LU2471134796.USD","SG9999015952.SGD","LU0689472784.USD","LU1127390331.HKD","LU2237443382.USD","LU1917777945.USD","LU2237443622.USD","LU2023250504.SGD","LU1093756168.USD","SG9999013999.USD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00BFSS7M15.SGD","LU0889565916.HKD","IE0009355771.USD","LU2271345857.HKD","TMED","LU0820561818.USD","LU0354030511.USD","SG9999015978.USD","LU2461242641.AUD","LU2360106947.USD","LU2237443978.SGD","LU1868836591.USD","LU0234572021.USD","MEDI","LU2089284900.SGD","JDOC","LU0823434740.USD","FHLC","LU1989771016.USD","LU0471298694.HKD","MEDX","VHT","SGXZ31699556.SGD","LU1551013342.USD","PSCH","LU1974910355.USD","LU2108987350.USD","LU0198837287.USD","LU2491050154.USD","IE00BK4W5M84.HKD","LLYX","LU1057294990.SGD","LU2756315664.SGD","LU1983299246.USD","LU1548497426.USD","IE00BKDWB100.SGD","LU1814569148.SGD","LU0079474960.USD","LU0256863811.USD","LU1267930730.SGD","ALKS","LU0353189763.USD","LU2750360997.AUD","LU0094547139.USD","LU2211815571.USD","IE00BFSS8Q28.SGD","IE00BK4W5L77.USD","LU0786609619.USD","LU0640476718.USD","LU2468319806.SGD","SGXZ57979304.SGD","GB00BDT5M118.USD","LU0683600562.USD","LU2168564149.EUR","LU2028103732.USD","IE00B7KXQ091.USD","LU1979441026.SGD","SG9999001176.USD","IE0001KFT4U8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656597","title":"Corcept Therapeutics (CORT) Stock Could Be Undervalued Despite Mixed Broader Checks","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656597","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656597?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:39","pubTimestamp":1786030757,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics stock has delivered a very large 5 year return, yet its recent valuation checks suggest the shares are not an obvious bargain at today's level.\n\nOver the past 5 years, Corcept Therapeutics has returned about 4.4x, which sets a high bar for any further upside to be justified by fundamentals.\nInvestor focus is currently on how demand for the company’s treatments and late stage pipeline can support future revenue, while execution and clinical outcomes across those programs...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-stock-could-be-undervalued-despite","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-stock-could-be-undervalued-despite","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","LU0566484027.USD","FBT","CORT","BK4532","LU1559883803.SGD","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572786","title":"Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572786","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572786?lang=en_us&edition=fundamental","pubTime":"2026-08-06 07:25","pubTimestamp":1785972320,"startTime":"0","endTime":"0","summary":"The latest update is out from Takeda Pharmaceutical Co ( ($JP:4502) ). Takeda has secured U.S. FDA approval for ORZEYFUL, an oral orexin receptor 2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-wins-first-in-class-u-s-approval-for-orexin-therapy-in-narcolepsy-type-1?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-wins-first-in-class-u-s-approval-for-orexin-therapy-in-narcolepsy-type-1?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","MRNX","MRNY","IBB","MEDI","IYH","TBXU","RSPH","GDOC","LFSC","PSCH","TECB","BBP","BMED","BK4585","GNMX","FRTY","XLVX","LABU","PINK","NVIB","SYNB","IEIH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657571260","title":"Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon Disposes of 1,540 Common Shares Worth $175,806.40","url":"https://stock-news.laohu8.com/highlight/detail?id=2657571260","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657571260?lang=en_us&edition=fundamental","pubTime":"2026-08-06 06:11","pubTimestamp":1785967865,"startTime":"0","endTime":"0","summary":"Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon disposes of 1,540 common shares worth $175,806.40Corcept Therapeutics Chief Accounting & Technology Officer Joseph Douglas Lyon sold 1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL4ffvrh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon Disposes of 1,540 Common Shares Worth $175,806.40","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4007","CORT","FBT","BK4532","LU0566484027.USD","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657208075","title":"Arcutis Q2 Revenue Rises on Demand for Zoryve, Lifts 2026 Sales Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657208075","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657208075?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:08","pubTimestamp":1785960518,"startTime":"0","endTime":"0","summary":"Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlookOverviewUS dermatology drug maker's Q2 product revenue rose 59% yr/yr, driven by ZORYVE demandCompany raised 2026 full-year net p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421A9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","ARQT","LU2065170008.USD","LU2065171402.SGD","BK4139","ACAD","LU2065171311.SGD","PSCH","HELX","KRYS","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657543991","title":"United Therapeutics Q2 Revenue Misses Estimates on Ebulized Tyvaso Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2657543991","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657543991?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:38","pubTimestamp":1785926324,"startTime":"0","endTime":"0","summary":"United Therapeutics Q2 revenue misses estimates on Ebulized Tyvaso weaknessOverviewRare disease drugmaker's Q2 revenue fell 2% yr/yr, missing analyst expectationsQ2 net income rose 8% yr/yr; diluted E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420FK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","UTHR","TVTX","BK4532","LU1699723380.USD","KRYS","LU1571399168.USD","HELX","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657404561","title":"Ultragenyx Q2 Revenue Rises 28% to Record High, Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2657404561","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657404561?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:18","pubTimestamp":1785874711,"startTime":"0","endTime":"0","summary":"Ultragenyx Q2 revenue rises 28% to record high, net loss narrowsOverviewUS biopharma for rare diseases reported Q2 revenue up yr/yr to highest in company historyNet loss for Q2 narrowed yr/yr, with lo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N441167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RARE","BK4588","BK4585","HRMY","KRYS","MEDI","BK4139","PSCH","RYTM","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656300056","title":"Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $98,821.72","url":"https://stock-news.laohu8.com/highlight/detail?id=2656300056","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656300056?lang=en_us&edition=fundamental","pubTime":"2026-08-04 07:10","pubTimestamp":1785798604,"startTime":"0","endTime":"0","summary":"Alkermes EVP, CLO David Joseph Gaffin sells 2,034 shares for $98,821.72David Joseph Gaffin, EVP and chief legal officer, sold 2,034 ordinary shares on Aug. 3, 2026 at USD 48.58.His direct stake fell t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL9zXC08:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $98,821.72","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSIL","FBT","ALKS","PSCH","MEDX","IBRN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}